Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Xenograft Models of Multiple Myeloma Reveal That PU.1 Serves As a Tumor Suppressor for Multiple Myeloma

Nao Nishimura, MD, Shinya Endo, MD, Niina Ueno, MD, Shikiko Ueno, MD PhD, Hiromichi Yuki, MD PhD, Hiroyuki Hata, MD PhD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2014) 124 (21): 2047.

https://doi.org/10.1182/blood.V124.21.2047.2047

Published: 2014

Journal Articles

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

Shinya Endo, MD, Hiromichi Yuki, MD PhD, Yoshihiro Komohara, MD PhD, Shikiko Ueno, MD PhD, Nao Nishimura, MD, Niina Ueno, MD, Hiro Tatetsu, MD PhD, Motohiro Takeya, MD PhD, Hiroyuki Hata, MD PhD, Seiji Okada, MD PhD, Daniel G. Tenen, MD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2014) 124 (21): 29.

https://doi.org/10.1182/blood.V124.21.29.29

Published: 2014

Journal Articles

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Hiromichi Yuki, Shikiko Ueno, Hiro Tatetsu, Hiroaki Niiro, Tadafumi Iino, Shinya Endo, Yawara Kawano, Yoshihiro Komohara, Motohiro Takeya, Hiroyuki Hata, Seiji Okada, Toshiki Watanabe, Koichi Akashi, Hiroaki Mitsuya, Yutaka Okuno

Blood (2013) 121 (6): 962–970.

https://doi.org/10.1182/blood-2012-05-431429

Published: 2013

Includes: Supplemental data

Journal Articles

Monocarboxylate Transporters Play an Important Role in Aerobicglycolysis in Multiple Myeloma

Shiho Fujiwara, MD, Naoko Wada, MD, Yawara Kawano, MD, Hiromichi Yuki, MD, Yutaka Okuno, MD, PhD, Kisato Nosaka, MD, PhD, Hiroaki Mitsuya, Hiroyuki Hata, MD, PhD

Blood (2012) 120 (21): 1821.

https://doi.org/10.1182/blood.V120.21.1821.1821

Published: 2012

Journal Articles

Hypoxia Reduces CD138 Expression and Induces Immature Phenotype in Myeloma Cells

Yawara Kawano, MD, Shiho Fujiwara, MD, Naoko Wada, MD, Hiromichi Yuki, MD, Hiroaki Mitsuya, MD, PhD, Hiroyuki Hata, MD, PhD

Blood (2012) 120 (21): 3956.

https://doi.org/10.1182/blood.V120.21.3956.3956

Published: 2012

Journal Articles

Aerobic Glycolysis: A Possible Target for Treating Multiple Myeloma (MM) with High Serum LDH Levels

Shiho Fujiwara, MD, Yawara Kawano, MD, Hiromichi Yuki, MD, Yutaka Okuno, MD, PhD, Kisato Nosaka, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hiroyuki Hata, MD, PhD

Blood (2011) 118 (21): 1799.

https://doi.org/10.1182/blood.V118.21.1799.1799

Published: 2011

Journal Articles

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Hiromichi Yuki, MD, Shikiko Ueno, MD, PhD, Hiroaki Niiro, MD, PhD, Hiro Tatetsu, MD, PhD, Hiroyuki Hata, MD, PhD, Toshiki Watanabe, MD, PhD, Seiji Okada, MD, Ph.D, Koichi Akashi, MD, PhD., Hiroaki Mitsuya, Professor, Yutaka Okuno, MD, PhD

Blood (2011) 118 (21): 2628.

https://doi.org/10.1182/blood.V118.21.2628.2628

Published: 2011

Journal Articles

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Yawara Kawano, MD, Shiho Fujiwara, MD, Hiromichi Yuki, MD, Hiro Tatetsu, MD, PhD, Hiroshi Yamasaki, MD, PhD, Akira Sakai, MD, PhD, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hiroyuki Hata, MD, PhD

Blood (2011) 118 (21): 3939.

https://doi.org/10.1182/blood.V118.21.3939.3939

Published: 2011

Journal Articles

CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress Response and Low Sensitivity to Bortezomib

Yawara Kawano, Yoshitaka Kikukawa, Miki Nakamura, Yutaka Okuno, MD, PhD, Hiromichi Yuki, Shiho Fujiwara, Hiroaki Mitsuya, Hiroyuki Hata, MD, PhD

Blood (2010) 116 (21): 616.

https://doi.org/10.1182/blood.V116.21.616.616

Published: 2010

Journal Articles

Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events

Yawara Kawano, Shikiko Ueno, Masahiro Abe, MD, Yoshitaka Kikukawa, Hiromichi Yuki, Kenichi Iyama, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, Hiroyuki Hata, MD, PhD

Blood (2010) 116 (21): 2975.

https://doi.org/10.1182/blood.V116.21.2975.2975

Published: 2010

NARROW

Xenograft Models of Multiple Myeloma Reveal That PU.1 Serves As a Tumor Suppressor for Multiple Myeloma

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Monocarboxylate Transporters Play an Important Role in Aerobicglycolysis in Multiple Myeloma

Hypoxia Reduces CD138 Expression and Induces Immature Phenotype in Myeloma Cells

Aerobic Glycolysis: A Possible Target for Treating Multiple Myeloma (MM) with High Serum LDH Levels

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress Response and Low Sensitivity to Bortezomib

Production of TRAIL by Multiple Myeloma Cells: a Potential Prediction Marker for Skeletal-Related Events

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only